HomeProductsBioactive CompoundsMetabolic EnzymesFXRCilofexor
Chemical structure of CAS 1418274-28-8

Cilofexor

CAS No.1418274-28-8
MDL No.MFCD31731099
MFC28H22Cl3N3O5
MW586.80
InChI KeyKZSKGLFYQAYZCO-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1418274-28-8
Product NameCilofexor

Biological Targets

NR1H4

Associated Conditions

non-alcoholic steatohepatitis·sclerosing cholangitis·non-alcoholic fatty liver disease·primary biliary cirrhosis
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease.

The Journal of pharmacology and experimental therapeutics • Vol. 389, Issue 1 • 2024
PMID: 38409114DOI: 10.1124/jpet.123.001900

Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach.

Biochemical pharmacology • Vol. 209 • 2023
PMID: 36792038DOI: 10.1016/j.bcp.2023.115452

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.

Journal of medicinal chemistry • Vol. 63, Issue 10 • 2020
PMID: 31930920DOI: 10.1021/acs.jmedchem.9b01701

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.

Hepatology (Baltimore, Md.) • Vol. 70, Issue 3 • 2019
PMID: 30661255PMC: PMC6767458DOI: 10.1002/hep.30509

Documentation

Similar Products